Australia markets close in 2 hours 13 minutes
  • ALL ORDS

    7,753.10
    -18.70 (-0.24%)
     
  • ASX 200

    7,544.30
    -13.80 (-0.18%)
     
  • AUD/USD

    0.6922
    -0.0002 (-0.03%)
     
  • OIL

    73.51
    +0.12 (+0.16%)
     
  • GOLD

    1,885.90
    +9.30 (+0.50%)
     
  • BTC-AUD

    33,119.21
    -783.71 (-2.31%)
     
  • CMC Crypto 200

    525.81
    -11.05 (-2.06%)
     
  • AUD/EUR

    0.6413
    +0.0002 (+0.03%)
     
  • AUD/NZD

    1.0940
    +0.0005 (+0.05%)
     
  • NZX 50

    12,197.15
    +44.95 (+0.37%)
     
  • NASDAQ

    12,573.36
    -229.74 (-1.79%)
     
  • FTSE

    7,901.80
    +81.64 (+1.04%)
     
  • Dow Jones

    33,926.01
    -127.89 (-0.38%)
     
  • DAX

    15,476.43
    -32.77 (-0.21%)
     
  • Hang Seng

    21,218.31
    -442.16 (-2.04%)
     
  • NIKKEI 225

    27,801.97
    +292.51 (+1.06%)
     

Tiziana Life Sciences to Host Investor Call

Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd.

NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an investor call and webcast on Thursday, November 10 2022 at 10 a.m. ET.

Dial-in details and webcast information will be provided on the morning of November 10.

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd

Hana Malik, Business Development and Investor Relations Manager
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com